China/Asia TMT

Shawn Yang

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>3690HK / 1024HK:  Douyin launches local services partner conference (-)</li>
<li>NIO: Wait times for NIO ES7 shortened to 3 weeks (-)</li>
<li>LEGN:  Legend Bio announced positive Caltitude-4 data, raising private placement of US$200mn（/）</li>
</ul>


3690HK / 1024HK:  Douyin launches local services partner conference (-)
NIO: Wait times for NIO ES7 shortened to 3 weeks (-)
LEGN:  Legend Bio announced positive Caltitude-4 data, raising private placement of US$200mn（/）


China TMT Update (Apr.26) - 3690HK/ 1024HK/NIO/LEGN:Douyin Launches Local Services Conference

<ul>
<li>700 HK： &lt; Metal Slug: Awakenings &gt; officially launches（ + ）</li>
<li>LEGN: CARVYKTI C1Q23 revenue rebounded QoQ but below our expectation(/)</li>
<li>JD/BABA/VIPS/3690.HK: March NBS consumption strengthened, especially apparel and catering (-/+/+/+)</li>
</ul>


700 HK： &lt; Metal Slug: Awakenings &gt; officially launches（ + ）
LEGN: CARVYKTI C1Q23 revenue rebounded QoQ but below our expectation(/)
JD/BABA/VIPS/3690.HK: March NBS consumption strengthened, especially apparel and catering (-/+/+/+)


China TMT Update（Apr.20）700 HK/Jd/Baba/Vips/3690.hk/LEGN:  Launches

<ul>
<li>LI: Li Auto unveils all-electric solution and makes its AD Max 3.0 free (+)</li>
<li>9995HK: Hengrui disclosed the results of its HER2 ADC phase III clinical trial and will become a strong competitor in the ADC track(-)</li>
<li>LGEN:Novartis Signs Legend Bio/Johnson &amp; Johnson to help produce CAR-T(+)</li>
</ul>


LI: Li Auto unveils all-electric solution and makes its AD Max 3.0 free (+)
9995HK: Hengrui disclosed the results of its HER2 ADC phase III clinical trial and will become a strong competitor in the ADC track(-)
LGEN:Novartis Signs Legend Bio/Johnson &amp; Johnson to help produce CAR-T(+)


China TMT Update (Apr.19) - LI/9995HK/LGEN:Li Auto Unveils All-Electric Solution

Research from EqualOcean, EqualOcean

EqualOcean

Research from EqualOcean

EqualOcean is an investment research firm and information service provider focusing on China's Technology, Automotive and Consumer Internet sectors. With unique research and due diligence methodology, we provide tailored insights into a wide range of industries and companies, empowering our clients' value-added decisions.

Founded in 2014, EqualOcean is headquartered in Beijing and has offices in Shanghai, Shenzhen and New York.

<ul><li>GT (Cell and Gene Therapy) is a sector with high growth potential.</li><li>CAR-T, as one of the main CGT currently, presents great value for both doctors and patients.</li><li>This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.</li></ul>

GT (Cell and Gene Therapy) is a sector with high growth potential.CAR-T, as one of the main CGT currently, presents great value for both doctors and patients.This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.

Opportunities and Challenges Hidden in the CGT Industry in China

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>New policy was released to support the development of surgical robots in China, which would be short-term catalyst for related companies, but it may not bring high profits.</li>
<li>In fact, since March, it may not be appropriate for healthcare companies to use the COVID-19 as a reason if their performance in the following months is not as expected.</li>
<li>Before DRGs/DIP policy becomes very “lethal”, there is a “policy vacuum period” in the next two or three years, which is a good opportunity to go long in China healthcare.</li>
</ul>


New policy was released to support the development of surgical robots in China, which would be short-term catalyst for related companies, but it may not bring high profits.
In fact, since March, it may not be appropriate for healthcare companies to use the COVID-19 as a reason if their performance in the following months is not as expected.
Before DRGs/DIP policy becomes very “lethal”, there is a “policy vacuum period” in the next two or three years, which is a good opportunity to go long in China healthcare.


China Healthcare Weekly (Jan.27) - Surgical Robots New Policy, COVID-19 Update, Policy Vacuum Period

China

Legend Biotech Corporation operates as a biopharmaceutical company. The Company engages in discovery and development of novel cell therapies for oncology and other indications. Legend Biotech serves customers in the State of New Jersey.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Legend Biotech Corp (LEGN US)

China TMT Update (Apr.26) - 3690HK/ 1024HK/NIO/LEGN:Douyin Launches Local Services Conference

3690HK/1024HK: Douyin launches local services partner conference (-)；NIO: Wait times for NIO ES7 shortened to 3 weeks (-)；LEGN: Legend Bio...

Blue Lotus Research Institute

China TMT Update（Apr.20）700 HK/Jd/Baba/Vips/3690.hk/LEGN: Launches

700HK： <Metal Slug: Awakenings> officially launches（+）; LEGN: CARVYKTI C1Q23 revenue rebounded QoQ but below our expectation(/); JD/BABA/VIPS...

Blue Lotus Research Institute

China TMT Update (Apr.19) - LI/9995HK/LGEN:Li Auto Unveils All-Electric Solution

LI: Li Auto unveils all-electric solution (+)； 9995HK: Hengrui disclosed the results of its HER2 ADC phase III clinical trial；LGEN:Novartis Signs...

Blue Lotus Research Institute

Opportunities and Challenges Hidden in the CGT Industry in China

GT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors...

EqualOcean

China Healthcare Weekly (Jan.27) - Surgical Robots New Policy, COVID-19 Update, Policy Vacuum Period

New policy released to support development of surgical robot. COVID-19 is no longer an excuse for company's poor performance. It's a good time to...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)